Skip to main content

Generic Genosyl Availability

Last updated on Oct 6, 2021.

Genosyl is a brand name of nitric oxide, approved by the FDA in the following formulation(s):

GENOSYL (nitric oxide - gas;inhalation)

  • Manufacturer: VERO BIOTECH
    Approval date: December 20, 2019
    Strength(s): 800PPM [RLD]

Has a generic version of Genosyl been approved?

No. There is currently no therapeutically equivalent version of Genosyl available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Genosyl. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
    Patent 10,124,142
    Issued: November 13, 2018
    Assignee(s): VERO BIOTECH LLC

    Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.

    Patent expiration dates:

    • August 18, 2025
      ✓ 
      Patent use: A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT
  • Nitrogen dioxide storage cassette
    Patent 10,213,572
    Issued: February 26, 2019
    Assignee(s): VERO BIOTECH LLC

    A nitric oxide delivery system can include a cassette which is a single use disposable component used to store liquid N2O4, activate upon operator demand, convert N2O4 to NO2 via a heating element(s) controlled by a console to deliver NO2 at a controlled flow rate, direct concentrated NO2 to a contained pair of conversion cartridges and exhaust NO gas to the console for delivery to the patient.

    Patent expiration dates:

    • February 12, 2036
      ✓ 
      Drug product
  • Patent 10,737,051

    Patent expiration dates:

    • October 20, 2035
      ✓ 
      Drug product
  • Patent 10,814,092

    Patent expiration dates:

    • October 17, 2025
      ✓ 
      Patent use: A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT
  • Patent 10,926,054

    Patent expiration dates:

    • August 13, 2029
      ✓ 
      Drug product
  • Patent 11,103,669

    Patent expiration dates:

    • June 21, 2030
      ✓ 
      Drug product
  • Simple nitric oxide generator for ambulatory and/or bedside inhaled no treatment
    Patent 6,758,214
    Issued: July 6, 2004
    Inventor(s): David H.; Fine & Freeman W.; Fraim & George; Jarvis
    Assignee(s): CyTerra Corporation

    A nitric oxide delivery system for delivering nitric oxide to a patient to treat a medical condition includes a container, a nitric oxide generation chamber, and a pump. The container is designed to contain a nitrogen-containing compound. The nitric oxide generation chamber includes a heat source and is designed to generate nitric oxide from the nitrogen-containing compound. The pump is designed to transfer at least a part of the nitrogen-containing compound from the container to the nitric oxide generation chamber.

    Patent expiration dates:

    • February 23, 2022
      ✓ 
      Drug product
  • Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
    Patent 7,560,076
    Issued: July 14, 2009
    Inventor(s): Rounbehler; David R. & Fine; David H.
    Assignee(s): GENO LLC

    Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.

    Patent expiration dates:

    • April 21, 2027
      ✓ 
      Drug product
  • Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
    Patent 7,618,594
    Issued: November 17, 2009
    Inventor(s): Rounbehler; David R. & Fine; David H.
    Assignee(s): GeNO LLC

    A nitric oxide delivery system, which includes a gas bottle having nitrogen dioxide in air, converts nitrogen dioxide to nitric oxide and employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. A nitric oxide delivery system may be used to generate therapeutic gas including nitric oxide for use in delivering the therapeutic gas to a mammal.

    Patent expiration dates:

    • October 17, 2026
      ✓ 
      Drug product
  • Kit for the conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
    Patent 7,947,227
    Issued: May 24, 2011
    Inventor(s): Fine; David H. & Rounbehler; David P. & Vasquez; Greg
    Assignee(s): Geno LLC

    A nitric oxide delivery system, which includes a gas bottle having nitrogen dioxide in air, converts nitrogen dioxide to nitric oxide and employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. A nitric oxide delivery system may be used to generate therapeutic gas including nitric oxide for use in delivering the therapeutic gas to a mammal.

    Patent expiration dates:

    • October 17, 2026
      ✓ 
      Patent use: A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT
  • Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
    Patent 8,057,742
    Issued: November 15, 2011
    Inventor(s): Rounbehler; David R. & Fine; David H.
    Assignee(s): Geno LLC

    A nitric oxide delivery system, which includes a gas bottle having nitrogen dioxide in air, converts nitrogen dioxide to nitric oxide and employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. A nitric oxide delivery system may be used to generate therapeutic gas including nitric oxide for use in delivering the therapeutic gas to a mammal.

    Patent expiration dates:

    • January 18, 2026
      ✓ 
      Patent use: A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT
  • Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
    Patent 8,226,916
    Issued: July 24, 2012
    Inventor(s): Rounbehler; David R. & Fine; David H.
    Assignee(s): Geno LLC

    Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.

    Patent expiration dates:

    • August 18, 2025
      ✓ 
      Patent use: A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT
  • Systems and devices for generating nitric oxide
    Patent 8,607,785
    Issued: December 17, 2013
    Assignee(s): Geno LLC

    Various systems and devices for generating nitric oxide are disclosed herein. According to one embodiment, the device includes a body having an inlet, an outlet, and a porous solid matrix positioned with the body. The porous solid matrix is coated with an aqueous solution of an antioxidant, wherein the inlet is configured to receive a gas flow and fluidly communicate the gas flow to the outlet through the solid matrix to convert nitrogen dioxide in the gas flow into nitric oxide. The porous solid matrix allows the device to be used in any orientation. Additionally, the porous solid matrix provides a rigid structure suitable to withstand vibrations and abuse without compromising device functionality.

    Patent expiration dates:

    • July 14, 2030
      ✓ 
      Drug product
  • Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
    Patent 8,609,028
    Issued: December 17, 2013
    Assignee(s): Geno LLC

    Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.

    Patent expiration dates:

    • August 18, 2025
      ✓ 
      Patent use: A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT
  • Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
    Patent 8,821,801
    Issued: September 2, 2014
    Assignee(s): Geno LLC

    A nitric oxide delivery system, which includes a gas bottle having nitrogen dioxide in air, converts nitrogen dioxide to nitric oxide and employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. A nitric oxide delivery system may be used to generate therapeutic gas including nitric oxide for use in delivering the therapeutic gas to a mammal.

    Patent expiration dates:

    • August 18, 2025
      ✓ 
      Drug product
  • Systems and devices for generating nitric oxide
    Patent 8,944,049
    Issued: February 3, 2015
    Assignee(s): GENO LLC

    Various systems and devices for generating nitric oxide are disclosed herein. According to one embodiment, the device includes a body having an inlet, an outlet, and a porous solid matrix positioned with the body. The porous solid matrix is coated with an aqueous solution of an antioxidant, wherein the inlet is configured to receive a gas flow and fluidly communicate the gas flow to the outlet through the solid matrix to convert nitrogen dioxide in the gas flow into nitric oxide. The porous solid matrix allows the device to be used in any orientation. Additionally, the porous solid matrix provides a rigid structure suitable to withstand vibrations and abuse without compromising device functionality.

    Patent expiration dates:

    • August 13, 2029
      ✓ 
      Drug product
  • Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
    Patent 9,522,249
    Issued: December 20, 2016
    Assignee(s): GENO LLC

    Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.

    Patent expiration dates:

    • August 18, 2025
      ✓ 
      Drug product
  • Systems and devices for generating nitric oxide
    Patent 9,604,028
    Issued: March 28, 2017
    Assignee(s): GENO LLC

    Various systems and devices for generating nitric oxide are disclosed herein. According to one embodiment, the device includes a body having an inlet, an outlet, and a porous solid matrix positioned with the body. The porous solid matrix is coated with an aqueous solution of an antioxidant, wherein the inlet is configured to receive a gas flow and fluidly communicate the gas flow to the outlet through the solid matrix to convert nitrogen dioxide in the gas flow into nitric oxide. The porous solid matrix allows the device to be used in any orientation. Additionally, the porous solid matrix provides a rigid structure suitable to withstand vibrations and abuse without compromising device functionality.

    Patent expiration dates:

    • August 13, 2029
      ✓ 
      Patent use: A METHOD FOR DELIVERING NITRIC OXIDE TO A PATIENT WITH PULMONARY HYPERTENSION OR HYPOXIA
  • Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
    Patent 9,701,538
    Issued: July 11, 2017
    Assignee(s): GENO LLC

    Various systems, devices, NO2 absorbents, NO2 scavengers and NO2 recuperator for generating nitric oxide are disclosed herein. According to one embodiment, an apparatus for converting nitrogen dioxide to nitric oxide can include a receptacle including an inlet, an outlet, a surface-active material coated with an aqueous solution of ascorbic acid and an absorbent wherein the inlet is configured to receive a gas flow and fluidly communicate the gas flow to the outlet through the surface-active material and the absorbent such that nitrogen dioxide in the gas flow is converted to nitric oxide.

    Patent expiration dates:

    • January 28, 2029
      ✓ 
      Drug product
  • Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
    Patent 9,956,373
    Issued: May 1, 2018
    Assignee(s): GENO LLC

    A nitric oxide delivery system, which includes a gas bottle having nitrogen dioxide in air, converts nitrogen dioxide to nitric oxide and employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. A nitric oxide delivery system may be used to generate therapeutic gas including nitric oxide for use in delivering the therapeutic gas to a mammal.

    Patent expiration dates:

    • August 18, 2025
      ✓ 
      Patent use: A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT

More about Genosyl (nitric oxide)

Consumer resources

Other brands
INOmax, Noxivent

Professional resources

Related treatment guides

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.